$VRAX

RedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.

Biotech stocks rose on multiple catalysts. CareDx (CDNA) jumped 35.6% after Medicare finalized an LCD covering its transplant molecular testing, effective Aug. 30, 2026. AtaiBeckley (ATAI) gained 33.4% on an Eli Lilly (LLY) acquisition deal up to $3.8B. Abbott (ABT) rose 10.7% after Q2 results and raised FY26 adjusted EPS outlook to $5.45-$5.60.

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

Virax Biolabs Group Limited (Nasdaq: VRAX) said it will immediately exercise certain preferred investment options to buy up to 548,000 ordinary shares at a reduced $6.00 exercise price, down from $10.00. The company expects about $3.3 million gross proceeds. It will issue new Series A and Series B options/warrants and expects closing around July 10, 2026, subject to conditions.

Virax Biolabs Group Limited (VRAX) shares rose about 246% to $10.99 after the company said it signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect research-use immune profiling products. The deal covers Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, with near-term revenue via purchase orders.

Virax Biolabs Group (NASDAQ:VRAX) shares surged 228.13% to $10.43 after the company announced an exclusive supply agreement with Fosun Diagnostics covering six Southeast Asian markets. The deal provides immediate product supply via purchase orders and targets near-term revenue, including tuberculosis-related RUO research in Thailand. VRAX also completed a 1-for-25 share consolidation.

Virax Biolabs (NASDAQ: VRAX) said its subsidiary Virax Biolabs (UK) signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect RUO immune profiling products. The deal covers six Southeast Asian markets and enables near-term supply via purchase orders, with initial focus on tuberculosis research applications in Thailand. Fosun Pharma reported 2025 revenue of RMB41.662 billion (~US$5.8 billion).

Virax Biolabs Group (NASDAQ:VRAX) shares jumped 100% after it signed an exclusive multi-country supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling products. The deal covers six ASEAN markets and enables immediate supply via purchase orders, with initial focus on tuberculosis research in Thailand. ImmuneSelect is research-use-only, separate from Virax’s in-development diagnostic platform.

Virax Biolabs Group (NASDAQ:VRAX) saw short interest rise 173.2% in May, reaching 391,277 shares as of May 15 versus 143,206 on April 30, according to the report. About 16.4% of shares are shorted, with a days-to-cover ratio of 0.1 based on average volume. VRAX traded at $0.19, down $0.02, with heavy volume. Weiss reiterated a “sell (e+)” rating.

Virax Biolabs (NASDAQ: VRAX) reported early pilot data for ViraxImmune™, a blood-based test in development for Long COVID, ME/CFS and related post-acute infection syndromes. In the pilot dataset, it reported 88% specificity and 92% positive predictive value separating PAIS patients from healthy controls. The company said it has evaluated the test in 120+ subjects in an ongoing UK study and plans larger validation using samples from 300 additional participants starting Q4 2026, with results expec